As aap gears up for a US launch of LOQTEQ in H2, its FY15 guidance looks attainable. As expected, Q2 trading was soft, reflecting the lumpy orders in Biomaterials. Taking into account the combined effect of €5m lower net cash and rolling forward, we trim our valuation from €3.05 to €2.96/share.
